Human prostatic acid phosphatase in prostate carcinogenesis

Sakthivel Muniyan, Yu Wei Chou, Shou Qiang Ou-Yang, Ming-Fong Lin

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Human prostatic acid phosphatase (PAcP) is classically known as a prostate epithelium-specific differentiation antigen and was used as a surrogate marker for detecting prostate cancer (PCa) and monitoring its progression until the availability of prostate-specific antigen. Mature human PAcP protein is a 100 kDa glycoprotein containing two subunits of approximately 50 kDa each. Classically, two forms of human PAcP proteins have been identified: the cellular form (cPAcP) and the secretory form (sPAcP). Recent studies reveal the existence of a transmembrane form (TM-PAcP). While the function of sPAcP and TM-PAcP in human remains under further investigation, cPAcP functions as a neutral protein tyrosine phosphatase in PCa cells and dephosphorylates human epidermal growth factor receptor-2 (HER-2/ErbB-2/Neu) resulting in decreased cell growth as well as tumor suppression. Clinically, cPAcP levels decrease in PCa tissues and correlate with PCa progression, despite elevated levels of sPAcP in circulation. Data from xenograft animal models validate the tumor suppressor activity of cPAcP in prostate carcinomas. Further, activation of ErbB-2 upon knockdown of cPAcP expression results in a castration-resistant phenotype. Expression of PAcP is regulated by different factors in human PCa cells. PAcP is also a useful immunogen in PCa immunotherapy. Further investigation of the regulatory mechanism of cPAcP expression will likely provide valuable insights into novel PCa therapy.

Original languageEnglish (US)
Title of host publicationProstate Cancer
Subtitle of host publicationBiochemistry, Molecular Biology and Genetics
PublisherSpringer New York
Pages323-348
Number of pages26
ISBN (Electronic)9781461468288
ISBN (Print)9781461468271
DOIs
StatePublished - Jan 1 2013

Fingerprint

Prostate
Prostatic Neoplasms
Carcinogenesis
Prostate-Specific Antigen
Protein Tyrosine Phosphatases
Castration
Differentiation Antigens
prostatic acid phosphatase
Heterografts
Immunotherapy
Neoplasms
Glycoproteins
Proteins
Epithelium
Animal Models
Biomarkers
Carcinoma
Phenotype
Growth

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Muniyan, S., Chou, Y. W., Ou-Yang, S. Q., & Lin, M-F. (2013). Human prostatic acid phosphatase in prostate carcinogenesis. In Prostate Cancer: Biochemistry, Molecular Biology and Genetics (pp. 323-348). Springer New York. https://doi.org/10.1007/978-1-4614-6828-8_12

Human prostatic acid phosphatase in prostate carcinogenesis. / Muniyan, Sakthivel; Chou, Yu Wei; Ou-Yang, Shou Qiang; Lin, Ming-Fong.

Prostate Cancer: Biochemistry, Molecular Biology and Genetics. Springer New York, 2013. p. 323-348.

Research output: Chapter in Book/Report/Conference proceedingChapter

Muniyan, S, Chou, YW, Ou-Yang, SQ & Lin, M-F 2013, Human prostatic acid phosphatase in prostate carcinogenesis. in Prostate Cancer: Biochemistry, Molecular Biology and Genetics. Springer New York, pp. 323-348. https://doi.org/10.1007/978-1-4614-6828-8_12
Muniyan S, Chou YW, Ou-Yang SQ, Lin M-F. Human prostatic acid phosphatase in prostate carcinogenesis. In Prostate Cancer: Biochemistry, Molecular Biology and Genetics. Springer New York. 2013. p. 323-348 https://doi.org/10.1007/978-1-4614-6828-8_12
Muniyan, Sakthivel ; Chou, Yu Wei ; Ou-Yang, Shou Qiang ; Lin, Ming-Fong. / Human prostatic acid phosphatase in prostate carcinogenesis. Prostate Cancer: Biochemistry, Molecular Biology and Genetics. Springer New York, 2013. pp. 323-348
@inbook{b088eb26586146d6a1c229a8eeafd4c1,
title = "Human prostatic acid phosphatase in prostate carcinogenesis",
abstract = "Human prostatic acid phosphatase (PAcP) is classically known as a prostate epithelium-specific differentiation antigen and was used as a surrogate marker for detecting prostate cancer (PCa) and monitoring its progression until the availability of prostate-specific antigen. Mature human PAcP protein is a 100 kDa glycoprotein containing two subunits of approximately 50 kDa each. Classically, two forms of human PAcP proteins have been identified: the cellular form (cPAcP) and the secretory form (sPAcP). Recent studies reveal the existence of a transmembrane form (TM-PAcP). While the function of sPAcP and TM-PAcP in human remains under further investigation, cPAcP functions as a neutral protein tyrosine phosphatase in PCa cells and dephosphorylates human epidermal growth factor receptor-2 (HER-2/ErbB-2/Neu) resulting in decreased cell growth as well as tumor suppression. Clinically, cPAcP levels decrease in PCa tissues and correlate with PCa progression, despite elevated levels of sPAcP in circulation. Data from xenograft animal models validate the tumor suppressor activity of cPAcP in prostate carcinomas. Further, activation of ErbB-2 upon knockdown of cPAcP expression results in a castration-resistant phenotype. Expression of PAcP is regulated by different factors in human PCa cells. PAcP is also a useful immunogen in PCa immunotherapy. Further investigation of the regulatory mechanism of cPAcP expression will likely provide valuable insights into novel PCa therapy.",
author = "Sakthivel Muniyan and Chou, {Yu Wei} and Ou-Yang, {Shou Qiang} and Ming-Fong Lin",
year = "2013",
month = "1",
day = "1",
doi = "10.1007/978-1-4614-6828-8_12",
language = "English (US)",
isbn = "9781461468271",
pages = "323--348",
booktitle = "Prostate Cancer",
publisher = "Springer New York",

}

TY - CHAP

T1 - Human prostatic acid phosphatase in prostate carcinogenesis

AU - Muniyan, Sakthivel

AU - Chou, Yu Wei

AU - Ou-Yang, Shou Qiang

AU - Lin, Ming-Fong

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Human prostatic acid phosphatase (PAcP) is classically known as a prostate epithelium-specific differentiation antigen and was used as a surrogate marker for detecting prostate cancer (PCa) and monitoring its progression until the availability of prostate-specific antigen. Mature human PAcP protein is a 100 kDa glycoprotein containing two subunits of approximately 50 kDa each. Classically, two forms of human PAcP proteins have been identified: the cellular form (cPAcP) and the secretory form (sPAcP). Recent studies reveal the existence of a transmembrane form (TM-PAcP). While the function of sPAcP and TM-PAcP in human remains under further investigation, cPAcP functions as a neutral protein tyrosine phosphatase in PCa cells and dephosphorylates human epidermal growth factor receptor-2 (HER-2/ErbB-2/Neu) resulting in decreased cell growth as well as tumor suppression. Clinically, cPAcP levels decrease in PCa tissues and correlate with PCa progression, despite elevated levels of sPAcP in circulation. Data from xenograft animal models validate the tumor suppressor activity of cPAcP in prostate carcinomas. Further, activation of ErbB-2 upon knockdown of cPAcP expression results in a castration-resistant phenotype. Expression of PAcP is regulated by different factors in human PCa cells. PAcP is also a useful immunogen in PCa immunotherapy. Further investigation of the regulatory mechanism of cPAcP expression will likely provide valuable insights into novel PCa therapy.

AB - Human prostatic acid phosphatase (PAcP) is classically known as a prostate epithelium-specific differentiation antigen and was used as a surrogate marker for detecting prostate cancer (PCa) and monitoring its progression until the availability of prostate-specific antigen. Mature human PAcP protein is a 100 kDa glycoprotein containing two subunits of approximately 50 kDa each. Classically, two forms of human PAcP proteins have been identified: the cellular form (cPAcP) and the secretory form (sPAcP). Recent studies reveal the existence of a transmembrane form (TM-PAcP). While the function of sPAcP and TM-PAcP in human remains under further investigation, cPAcP functions as a neutral protein tyrosine phosphatase in PCa cells and dephosphorylates human epidermal growth factor receptor-2 (HER-2/ErbB-2/Neu) resulting in decreased cell growth as well as tumor suppression. Clinically, cPAcP levels decrease in PCa tissues and correlate with PCa progression, despite elevated levels of sPAcP in circulation. Data from xenograft animal models validate the tumor suppressor activity of cPAcP in prostate carcinomas. Further, activation of ErbB-2 upon knockdown of cPAcP expression results in a castration-resistant phenotype. Expression of PAcP is regulated by different factors in human PCa cells. PAcP is also a useful immunogen in PCa immunotherapy. Further investigation of the regulatory mechanism of cPAcP expression will likely provide valuable insights into novel PCa therapy.

UR - http://www.scopus.com/inward/record.url?scp=85025437884&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85025437884&partnerID=8YFLogxK

U2 - 10.1007/978-1-4614-6828-8_12

DO - 10.1007/978-1-4614-6828-8_12

M3 - Chapter

AN - SCOPUS:85025437884

SN - 9781461468271

SP - 323

EP - 348

BT - Prostate Cancer

PB - Springer New York

ER -